XLO XILIO THERAPEUTICS INC

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi’s 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 9:00 a.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at . A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting  and follow us on Twitter () and LinkedIn ().

This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.

For Investor Inquiries:

Melissa Forst

Argot Partners

For Media Inquiries: 

Julissa Viana

Vice President, Corporate Communications



EN
16/02/2023

Underlying

XLOXILIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on XILIO THERAPEUTICS INC

 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Pipeline and Business Updates and First Q...

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell engager programs utilizing Xilio’s novel ATACR and SEECR formats, with first development candidates anticipated in second half of 2025 WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage b...

May 8, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rul...

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.755 per share...

May 2, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a ...

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present updated data from its ongoing Phase 2 clinical trial investigating vilastobart, a tumor-activated,...

April 23, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Ru...

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 22,900 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. The stock options have an exercise...

April 4, 2025 1 EN
 PRESS RELEASE
Free
XLO XILIO THERAPEUT...

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth ...

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for PSMA, CLDN18.2 and STEAP1 Announced collaboration with AbbVie in the first quarter of 2025 to develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers WALTHAM, Mass., March 11, 2025 ...

March 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch